NASDAQ:NKTX
Looking like a technical reversal on the daily chart - MACD, TTM, and MACD look very resilient after a selloff.
Analysts set price targets at 15$, indicators seem to match up with this. Earnings in 17 days and mid-year treatment trials could be catalysts to move the price towards this target. Earlier results were promising.
Make sure to manage...
NASDAQ:NKTX is a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. While highly speculative, the daily charts have presented a purchasing opportunity after a stock offering to raise capital.
MACD and TTM Squeeze tend to be reversing, and selling pressure seems to...
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor...
Bullish
- Needs to clear neckline
- Broke downward trendline
- Not fantastic fundamental
Entry idea
- For members
Stop loss depending on entry and risk appetite. But always set meaningful stops.
“The only source of knowledge is experience”
Cheers and happy trading!
NKTX LONG SET UP
Sector: Health Technology
Industry: Biotechnology
Employees: ---
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Top 10%...
